Nuo Therapeutics, Inc. Cash Flow Statement
AURX|8 years of annual SEC 10-K data (FY2010-FY2017)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Nuo Therapeutics, Inc. used $5M in operating cash flow in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -45.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$15.0M | -$5.7M | -$52.8M | -$18.9M | -$20.2M | -$19.8M | -$3.5M | -$6.8M |
| Depreciation & Amortization | $1.1M | $836.2K | $433.0K | $613.5K | $1.1M | $1.2M | $631.2K | $440.2K |
| Operating Cash Flow | -$4.9M | -$7.8M | -$14.4M | -$17.4M | -$11.4M | -$11.4M | -$4.2M | -$3.5M |
| Capital Expenditures | - | - | $698.2K | $483.0K | $750.7K | - | $66.4K | $774.6K |
| Free Cash Flow | - | - | -$15.1M | -$17.9M | -$12.2M | - | -$4.3M | -$4.3M |
| Share Buybacks | $471 | - | - | - | - | - | - | - |
| FCF Margin | - | - | -131.1% | -230.7% | -105.0% | - | -59.4% | -110.2% |